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A B S T R A C T
Insulin resistance, broadly deﬁned as the reduced ability of insulin to exert its biological action, has been as-
sociated with depression and cognitive dysfunction in observational studies. However, it is unclear whether
these associations are causal and whether they might be underpinned by other shared factors. To address this
knowledge gap, we capitalized on the stability of genetic biomarkers through the lifetime, and on their uni-
directional relationship with depression and cognition. Speciﬁcally, we determined the association between
quantitative measures of cognitive function and depression and genetic instruments of insulin resistance traits in
two large-scale population samples, the Generation Scotland: Scottish Family Health Study (GS: SFHS;
N=19,994) and in the UK Biobank (N=331,374). In the GS:SFHS, the polygenic risk score (PRS) for fasting
insulin was associated with verbal intelligence and depression while the PRS for the homeostasis model as-
sessment of insulin resistance was associated with verbal intelligence. Despite this overlap in genetic archi-
tecture, Mendelian randomization analyses in the GS:SFHS and in the UK Biobank samples did not yield evidence
for causal associations from insulin resistance traits to either depression or cognition. These ﬁndings may be due
to weak genetic instruments, limited cognitive measures and insuﬃcient power but they may also indicate the
need to identify other biological mechanisms that may mediate the relationship from insulin resistance to de-
pression and cognition.
1. Introduction
Insulin resistance (INS-R) is broadly deﬁned as the reduced biolo-
gical action of insulin at its target tissues. INS-R results in chronic hy-
perglycemia and dyslipidemia characterised by high levels of total
cholesterol and triglycerides, and low levels of high-density lipoprotein
(HDL) (Li et al., 2014). INS-R and dyslipidemia are also major com-
ponents of the metabolic syndrome (Alberti and Zimmet, 1998; Alberti
et al., 2009; Balkau and Charles, 1999; Grundy et al., 2005). INS-R and
the associated dyslipidemia are major risk factors for cardiovascular
disease and for cardiovascular adversity in type 2 diabetes (T2D) and
obesity (Alberti et al., 2009). In addition, insulin has signiﬁcant func-
tions within the brain (Fatemeh and Cory, 2013) where it is involved in
biological pathways relevant to neuronal survival (Mielke et al., 2006;
Valenciano et al., 2006), dendritic outgrowth (Cheng et al., 2003;
Govind et al., 2001), synaptic plasticity (Skeberdis et al., 2001; Wang
et al., 2003) and cognition, particularly learning and memory (Dou
et al., 2005; Wickelgren, 1980).
https://doi.org/10.1016/j.expneurol.2019.04.001
Received 20 November 2018; Received in revised form 26 March 2019; Accepted 3 April 2019
⁎ Corresponding author at: Department of Psychiatry, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY, USA.
E-mail address: sophia.frangou@mssm.edu (S. Frangou).
1 These authors contributed equally to this manuscript.
Experimental Neurology 316 (2019) 20–26
Available online 06 April 2019
0014-4886/ © 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
Accumulating evidence from observational studies suggests that
INS-R, and the associated dyslipidemia, inﬂuence cognition and psy-
chopathology. Studies of patients have shown that T2D is associated
with signiﬁcant cognitive dysfunction and increased risk of vascular
dementia and Alzheimer's disease (Biessels et al., 2006; Cooper et al.,
2015; Cosway et al., 2001; Leibson et al., 1997; Ott et al., 1999; Palta
et al., 2014; Peila et al., 2002; Riederer et al., 2017; Sadanand et al.,
2016). Studies of general population cohorts have found that lower
general cognitive ability at age 11 years is associated with higher risk of
developing T2D in middle adulthood while higher polygenic risk scores
for T2D are inversely associated with educational attainment
(Hagenaars et al., 2016; Mottus et al., 2013). In older adults, the as-
sociations between cognitive task underperformance and age-related
cognitive decline appear to be weak for the polygenic risk for T2D alone
(Luciano et al., 2014) and INS-R traits (Lamport et al., 2009; Young
et al., 2006) but become more pronounced when both INS-R and dys-
lipidemia are present (Yates et al., 2012). Collectively, these studies
link abnormalities in glycaemic control to dysfunction in global in-
tellectual function and in speciﬁc cognitive domains reﬂecting verbal
ﬂuency, processing speed, memory and cognitive ﬂexibility (Benedict
et al., 2012; Ekblad et al., 2015; Palta et al., 2014).
A parallel line of research has examined the relationship between
INS-R and psychopathology. Meta-analyses indicate that depression
increases the risk for the subsequent development of INS-R (Pan et al.,
2012; Penninx, 2017) and T2D (Knol et al., 2006; Mezuk et al., 2008).
INS-R alone is a rather modest predictor of depressive symptoms or
major depressive disorder (MDD) (Kan et al., 2013) but the association
with depression becomes more robust, both cross-sectionally and
longitudinally, when signiﬁcant dyslipidaemia is also present
(Marijnissen et al., 2017; van Reedt Dortland et al., 2010; Vogelzangs
et al., 2011; Vogelzangs et al., 2014).
The relationships between INS-R, cognition and depression are
likely to involve diverse and currently poorly understood biological
mechanisms. For example, previous literature implicates low grade
inﬂammation (Liu et al., 2012) as well as activation of the hypothala-
mic–pituitary–adrenocortical (HPA) axis and of the sympathetic ner-
vous system (Chrousos, 2000; Weber-Hamann et al., 2002). Lifestyle
choices and health maintenance decisions are also likely to play a sig-
niﬁcant role. Both depression and INS-R have been linked to higher
caloric intake and obesity (Grossniklaus et al., 2012; Luppino et al.,
2010; Preiss et al., 2013) and to low rates of exercise (Golden et al.,
2008; Konttinen et al., 2010; Vallance et al., 2011). Antidepressant
medications, which are the standard pharmacological treatment for
depression, are also known to induce weight gain and metabolic dys-
regulation (Hiles et al., 2016; Serretti and Mandelli, 2010). Dis-
ambiguating the contribution of INS-R to depression and cognition in
the context of this complex background remains a major challenge.
We sought to advance our understanding of the causality of INS-R
for depression and cognition by capitalizing on the lifetime stability of
genetic biomarkers and their unidirectional relationship with clinical
and cognitive phenotypes. To maximize statistical power and general-
izability, we used measures of depression and cognition from two large
genotyped population samples, the Generation Scotland: Scottish
Family Health Study (GS:SFHS; N=19,994) and the UK Biobank
(N=331,374). This allowed us to employ polygenic proﬁle scoring
(Purcell et al., 2009) and inverse-variance weighted (IVW) Mendelian
Randomization (MR) (Bowden et al., 2015; Davey Smith and Hemani,
2014; Smith and Ebrahim, 2004) to test genetic associations between
INS-R related traits, depression and cognition. We found that the
polygenic risk score (PRS) for fasting insulin was associated with verbal
intelligence and depression while the PRS for homeostasis model as-
sessment of insulin resistance (HOMA-IR) was associated only with
verbal intelligence. However, the MR analyses did not provide evidence
for causal associations from INS-R traits to either cognition or depres-
sion. It is possible that methodological issues such as weak genetic in-
struments, limited cognitive measures and insuﬃcient power may have
contributed to these results. Conversely, the associations of INS-R to
depression and cognition may not be causal despite some degree of
genetic overlap. This study therefore points to the need to extend the
scope of research in this ﬁeld to examine the mediating roles of other
biological mechanisms.
2. Materials and methods
2.1. Cohorts
Genetic, clinical, and cognitive data were extracted from two large-
scale population-based cohorts: the Generation Scotland: The Scottish
Family Health Study (GS:SFHS) and the UK Biobank.
2.1.1. Generation Scotland: the Scottish Family Health Study (GS:SFHS)
The GS:SFHS (www.generationscotland.co.uk) is a family- and po-
pulation-based study consisting of 23,690 participants recruited
through 125 general medical practices across Scotland (Smith et al.,
2006; Smith et al., 2013). Genome-wide genotyping data, depression
status and measures of logical memory, digit symbol coding, verbal
ﬂuency, and verbal intelligence were available for 19,994 individuals
(11,773 females) aged 18–99 years (mean age= 47.41 years,
SD=14.98) (Hagenaars et al., 2016; Marioni et al., 2016; Smith et al.,
2013; Zeng et al., 2016). A broad deﬁnition of depression was based on
participants' responses to a single question as to whether they had ever
been aﬀected with depression (Zeng et al., 2016). The prevalence of
self-reported lifetime depression in this sample was 10%. Cognition was
assessed using the logical memory and digit symbol coding subtests of
the Wechsler Memory Scale III (Wechsler, 1997), the Controlled Oral
Word Association Test (COWAT) (Benton and Hamsher, 1976) and the
Mill Hill vocabulary test for senior and junior synonyms combined
(Raven, 1958), a test designed to measure verbal intelligence. The
quality control processes relating to the genetic, clinical and cognitive
data have been described in full elsewhere (Smith et al., 2013; Zeng
et al., 2016). Ethical approval for GS:SFHS was granted by the Tayside
Research Ethics Committee (reference 05/S1401/89). All participants
provided written informed consent.
2.1.2. UK Biobank
The UK Biobank (www.ukbiobank.ac.uk) is a population-based co-
hort that has detailed health information and biological measures for
501,726 individuals recruited from across the UK (Bycroft et al., 2018).
The genetic and phenotypic data used in the current study were
available for 331,374 unrelated individuals (177,775 females) aged
39–73 years (mean age=57.2 years, SD= 8.1). Individuals with
probable Major Depressive Disorder (MDD) were self-identiﬁed based
on responses to questions about current and lifetime symptoms and
diagnosis of depression (Howard et al., 2018). The prevalence of this
depression phenotype was 17.4%. Cognitive function was measured
using the symbol digit substitution score (UK Biobank Field ID 20159),
reaction time (UK Biobank Field ID 20023), numeric memory score (UK
Biobank Field ID 20240), and trail making test (mean of UK Biobank
Fields 20,156 and 20,157). Detailed information regarding the de-
pression and cognitive variables available within UK Biobank has been
published previously (Hagenaars et al., 2016; Howard et al., 2018). The
quality control processes relating to the data analysed here have also
been described in detail elsewhere (Howard et al., 2018; Luciano et al.,
2018). The UK Biobank study was approved by the National Health
Service Research Ethics Service (approval letter dated 17th June 2011,
reference: 11/NW/0382). The analyses presented here were conducted
under UK Biobank application 4844.
2.2. Insulin-resistance related traits
The euglycemic insulin clamp (Matsuda and DeFronzo, 1999) and
the glucose tolerance tests (Bergman et al., 1987) are considered the
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gold standard methods for the measurement of INS-R in research, but
their use is cumbersome in clinical practice and infeasible in large,
population-based research studies. Here we consider three reliable
surrogate measures: fasting insulin (Laakso, 1993), fasting glucose and
the homeostasis model assessment of insulin resistance (HOMA-IR)
(Matthews et al., 1985), which is based on the dynamic relationship
between fasting glucose and corresponding insulin levels. We con-
sidered four further traits, HDL cholesterol, Low-density lipoprotein
(LDL) cholesterol, triglycerides and total cholesterol, which are com-
ponents of dyslipidaemia associated with INS-R (Li et al., 2014). In
total, we focus on seven, genetically overlapping traits, three re-
presenting changes in glycaemic control and four representing dysli-
pidaemia (Bulik-Sullivan et al., 2015).
2.3. Computation of polygenic risk scores in the GS:SFHS
Pleiotropy reﬂects the overlap between the genetic architecture of
two or more traits (Solovieﬀ et al., 2013) and can be assessed using data
from single-nucleotide polymorphism (SNP) genotyping. Polygenic
proﬁle scoring (Purcell et al., 2009) uses summary data from genome-
wide association studies (GWAS) to test whether genetic liability to a
particular trait is associated with another phenotype. Here we ex-
amined whether genetic liability, expressed as Polygenic Risk Scores
(PRS), to the seven INS-R traits described above, is associated with the
measures of cognition and depression available in 19,994 individuals
from the GS:SFHS. Speciﬁcally, polygenic risk scores were based on
GWAS results for HOMA-IR (Dupuis et al., 2010), fasting glucose
(Dupuis et al., 2010), fasting insulin (Dupuis et al., 2010), HDL cho-
lesterol (Willer et al., 2013), Low-density lipoprotein (LDL) cholesterol
(Willer et al., 2013), triglycerides (Willer et al., 2013) and total cho-
lesterol (Willer et al., 2013). Quality controlled autosomal SNPs in
GS:SFHS were entered in PRSice v1.25 (Euesden et al., 2015) to com-
pute the PRS of each trait at ﬁve SNP set P-value threshold cutoﬀs of
≤0.01,≤ 0.05,≤ 0.1,≤ 0.5 and≤ 1 from the corresponding GWAS
summary statistics.
2.4. Statistical analyses
2.4.1. Polygenic risk score analyses in the GS:SFHS
We implemented mixed linear model analyses in ASReml-R, to test
the association between the PRS of the seven INS-R related traits to
cognition and depression in the GS:SFHS; age, sex, the ﬁrst four multi-
dimensional scaling components to control population stratiﬁcation,
and each of the PRS in turn were ﬁtted as ﬁxed eﬀects. To control for
relatedness in the sample, the pedigree structure was ﬁtted as a random
eﬀect by creating the inverse of a relationship matrix using pedigree
kinship information. P-values for ﬁxed eﬀects ﬁtted in the model were
calculated using Wald's conditional F-test. After Bonferroni correction
for multiple testing, the threshold of signiﬁcance for the ﬁve SNP sets
(corresponding to the 5 threshold cut-oﬀs) and the seven INS-R related
traits was set at P < 1.4×10−3 [0.05/(5× 7)].
We note that Richardson et al. (2019) have already published a
detailed atlas of the associations between multiple PRS with numerous
diverse traits in the UK Biobank, including those of interest to this
paper.
2.4.2. Mendelian randomization in the GS:SFHS and UK Biobank
MR exploits the random assignment of genotypes at birth and their
stability throughout the lifetime to overcome limitations relating to
residual confounding (measured or unmeasured) and reverse causation
(Bowden et al., 2015; Davey Smith and Hemani, 2014; Smith and
Ebrahim, 2004). MR analyses use genetic variants to assess causal re-
lationships between exposures (here INS-R related traits) and outcomes
(here depression and cognition) (Fig. 1). MR analyses were conducted
separately in the GS:SFHS and UK Biobank. As instrumental variables
for INS-R we used the 53 SNPs (Supplementary Table S1) deﬁned by
Lotta and colleagues (Lotta et al., 2017). Lotta and colleagues used all
SNPs independently-associated with higher fasting insulin adjusted for
body mass index [from up to 108,557 participants of the Meta-Analyses
of Glucose and Insulin-related traits Consortium (MAGIC; https://www.
magicinvestigators.org)] and lower HDL cholesterol and higher trigly-
cerides [from up to 188,577 participants of Global Lipids Genetics
Consortium (GLGC; http://lipidgenetics.org)]. For fasting glucose,
fasting insulin, triglycerides, HDL, LDL, and total cholesterol we used
signiﬁcant GWAS hits available in the MR-Base GWAS catalogue
(Hemani et al., 2018) (detailed in Supplementary Table S2). Depression
and cognitive measures, as deﬁned in 2.1, were used as outcome vari-
ables. All two-sample MR analyses were performed using the MR-Base R
package (“TwoSampleMR”) version 0.4.8 (https://github.com/
MRCIEU/TwoSampleMR) using inverse variance weighted (IVW)
method and MR-Egger intercept tests. The IVW method is based on a
regression of the exposure and outcome genetic variant vectors with the
intercept constrained to zero, as described by Burgess and colleagues
(Burgess et al., 2013). In total, 10 two-sample MR tests were performed
and the threshold for signiﬁcance was set at P < 5×10−3 (0.05/10)
following Bonferroni correction for multiple testing.
3. Results
3.1. Polygenic risk score analyses in the GS:SFHS
In the GS:SFHS, at P < 1.4×10−3, the risk of depression was
positively associated with higher PRS for fasting insulin while verbal
intelligence (assessed with the Mill Hill Vocabulary test) was associated
with the PRS for fasting insulin and for HOMA-IR. At the nominal
threshold of statistical signiﬁcance (P < .05), additional associations
were found between depression and the PRS for HOMA-IR. At the same
level, the PRS for HOMA-IR was associated with processing speed (as-
sessed with the digit symbol substitution task), while verbal intelligence
was associated with the PRS for triglycerides and fasting glucose. The
results of all the PRS analyses in the GS:SFHS are described in Table 1.
According to Richardson et al. (2019; http://mrcieu.mrsoftware.
org/PRS_atlas/), in the UK Biobank depression and intelligence were
associated with all the INS-R polygenic risk scores; these results can be
accessed at http://mrcieu.mrsoftware.org/PRS_atlas
3.2. Mendelian randomization in the GS:SFHS and UK Biobank
The MR analyses provided no evidence of any signiﬁcant
(P < 5×10−3) causal associations from any INS-R related trait to
cognition and depression in either GS:SFHS or UK Biobank
(Supplementary Tables S3–S9).
Fig. 1. Model for two-sample Mendelian randomization study. Mendelian
randomization can be used to test if the exposure (insulin resistance) causally
inﬂuences the outcome (depression and cognition) by using instrumental ge-
netic variables (genome-wide signiﬁcant SNPs) associated with the exposure
that are unrelated to potential confounders and only aﬀect the outcome via the
exposure.
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4. Discussion
We sought to identify causal relationships between INS-R related
traits, cognition and depression in two large population-based cohorts
using polygenic proﬁling and Mendelian Randomization. The polygenic
proﬁling indicated a degree of overlap in the genetic architecture of
fasting insulin and HOMA-IR with depression and verbal intelligence.
The MR analyses however showed no evidence of signiﬁcant causal
relationships from INS-R related traits to depression and cognition.
Our results support observational studies in general population
samples reporting phenotypic associations between INS-R traits, cog-
nition (Lamport et al., 2009; Luciano et al., 2014; Yates et al., 2012;
Young et al., 2006) and depression (Kan et al., 2013; Pan et al., 2012;
Penninx, 2017). The polygenic risk score analyses in the GS:SFHS and
results available from similar analyses in the UK Biobank (Richardson
et al., 2019) show reproducibility for the association between the PRS
for fasting insulin and HOMA-IR with global measures of intelligence
and with the risk of depression. These ﬁndings suggest a degree of
genetic overlap between INS-R traits with depression and cognition.
However, the PRS approach is liable to yield substantive false positive
rates due to horizontal pleiotropy, the phenomenon whereby a gene (or
genes) inﬂuences multiple traits (Davey Smith and Hemani, 2014).
These pleiotropic eﬀects are very common and PRS scores for one trait
seem to be associated with multiple other traits (Richardson et al.,
2019).
Mendelian randomization (MR) enables further interrogation of
these genetic associations to identify causal pathways between genetic
risk factors and complex human traits (Bowden et al., 2015; Davey
Smith and Hemani, 2014; Smith and Ebrahim, 2004). In simple terms,
MR examines the eﬀect of INS-R on depression risk (or another trait) by
comparing the rates of depression in individuals with and without
genotypes that predispose to INS-R. As any particular genotype is ran-
domly assigned at birth and is not subject to reverse causation, the use
of genetic variants (such as SNPs) provides a way of “randomising” a
sample so that the causality of an observed association can be assessed.
Consistent with previous large-scale studies (Bulik-Sullivan et al., 2015;
Hagenaars et al., 2016), we found no evidence of directional associa-
tions from INS-R traits to cognition and depression. We therefore infer
that these associations are likely to be mediated by other mechanisms,
that are either consequent on INS-R or interact with INS-R pathways. In
the context of diabetes, chronic hyperglycemia may cause cognitive
impairment through direct adverse eﬀects on synaptic plasticity
(Jacobson et al., 2007) and neurogenesis (Alvarez et al., 2009). Hy-
perinsulinemia and INS-R can induce neuroglial energy deﬁcits (Zhao
and Alkon, 2001) and/or interfere with protein kinase C related sy-
naptic plasticity and neuronal repair (Nelson et al., 2008). Further,
hyperinsulinemia has been shown to promote amyloid accumulation
within the brain by limiting the degradation and clearance of the
amyloid-β peptide (Craft and Watson, 2004; Neumann et al., 2008).
Alternatively, the link between INS-R and cognitive dysfunction and
depression may be mediated by inﬂammatory pathways (Takeda et al.,
2010) and/or oxidative stress linked to mitochondrial dysfunction
(Cheng et al., 2010). Mitochondria integrate glucose and lipid meta-
bolism; speciﬁcally, insulin regulates mitochondrial metabolism and
oxidative capacity through PI3K/Akt signalling (Stiles, 2009). Finally,
cardiovascular pathology in the context of INS-R and diabetes may also
Table 1
Polygenic risk score anlysis of the seven INS-R traits on the depression and cognition in GS:SFHS (N=19,994) cohort.
Predicted Trait Polygenic predictor Cutoﬀ ⁎ Beta s.e. P-value VarExp Signiﬁcant (P < .0014) Nominally signiﬁcant (P < .05)
Depression HDL 1 −0.010378 0.007487 0.165714 1.08E-04 No No
Depression LDL 0.5 0.011319 0.007625 0.137723 1.28E-04 No No
Depression Total cholesterol 0.5 0.005902 0.007522 0.43266 3.48E-05 No No
Depression Triglycerides 1 0.01118 0.007793 0.151408 1.25E-04 No No
Depression Fasting glucose 0.5 −0.009554 0.007507 0.203142 9.13E-05 No No
Depression Fasting insulin 1 0.024652 0.00752 0.001045 6.08E-04 Yes Yes
Depression HOMA-IR 1 0.018765 0.007537 0.012783 3.52E-04 No Yes
Digit symbol coding HDL 0.01 0.009852 0.00644 0.126037 9.71E-05 No No
Digit symbol coding LDL 0.5 −0.007372 0.006594 0.263613 5.43E-05 No No
Digit symbol coding Total cholesterol 0.05 −0.002855 0.006469 0.658976 8.15E-06 No No
Digit symbol coding Triglycerides 1 −0.016496 0.006729 0.014224 2.72E-04 No Yes
Digit symbol coding Fasting glucose 0.05 −0.00782 0.006482 0.227695 6.11E-05 No No
Digit symbol coding Fasting insulin 1 −0.018656 0.006491 0.00405 3.48E-04 No Yes
Digit symbol coding HOMA-IR 1 −0.018927 0.006501 0.003597 3.58E-04 No Yes
Logical memory HDL 1 0.006623 0.007268 0.36217 4.39E-05 No No
Logical memory LDL 1 −0.005336 0.007407 0.471247 2.85E-05 No No
Logical memory Total cholesterol 0.1 0.002837 0.007295 0.697354 8.05E-06 No No
Logical memory Triglycerides 0.05 0.006401 0.007677 0.404398 4.10E-05 No No
Logical memory Fasting glucose 1 0.005722 0.007285 0.432181 3.27E-05 No No
Logical memory Fasting insulin 0.1 0.007012 0.007305 0.337074 4.92E-05 No No
Logical memory HOMA-IR 0.05 −0.004402 0.007312 0.547166 1.94E-05 No No
Verbal ﬂuency HDL 0.01 0.012377 0.007494 0.098621 1.53E-04 No No
Verbal ﬂuency LDL 0.01 0.011743 0.007544 0.119558 1.38E-04 No No
Verbal ﬂuency Total cholesterol 0.01 0.01696 0.007499 0.023714 2.88E-04 No Yes
Verbal ﬂuency Triglycerides 0.5 −0.007907 0.007846 0.313574 6.25E-05 No No
Verbal ﬂuency Fasting glucose 0.1 0.008079 0.007542 0.28406 6.53E-05 No No
Verbal ﬂuency Fasting insulin 0.5 −0.012408 0.007549 0.100234 1.54E-04 No No
Verbal ﬂuency HOMA-IR 0.01 −0.009219 0.007542 0.221546 8.50E-05 No No
Verbal intelligence HDL 0.05 0.006918 0.007094 0.329451 4.79E-05 No No
Verbal intelligence LDL 0.01 0.005926 0.007139 0.406471 3.51E-05 No No
Verbal intelligence Total cholesterol 0.1 0.01363 0.007135 0.056078 1.86E-04 No No
Verbal intelligence Triglycerides 0.01 0.018914 0.007479 0.011444 3.58E-04 No Yes
Verbal intelligence Fasting glucose 0.1 −0.016426 0.007126 0.021154 2.70E-04 No Yes
Verbal intelligence Fasting insulin 0.5 −0.027482 0.00713 0.000116 7.55E-04 Yes Yes
Verbal intelligence HOMA-IR 1 −0.02521 0.007143 0.000416 6.36E-04 Yes Yes
s.e.: Standard Error; VarExp: proportion of Predicted Trait variance which explained by Polygenic predictor; Signiﬁcant level after correction for the multiple test is
P < .0014.
⁎ Cutoﬀ: the most signiﬁcant polygenic risk score generated with P-value cut oﬀ threshold.
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play a signiﬁcant role. For example, in a sample of 2305 individuals
aged ≥60 years Marseglia and colleagues found that cognitive dys-
function was present only among participants who had both un-
controlled diabetes and vascular disorders/risk factors (Marseglia et al.,
2016).
There are several methodological considerations pertinent to in-
terpreting the current ﬁndings. A particular strength of this study is the
availability of data from two large general population samples in which
all participants were assessed using harmonised protocols; this contrasts
with most large-scale studies that rely on data pooled across diverse
cohorts. The instrumental variables used in the analyses were based on
the most up-to-date information from the largest GWAS. The polygenic
and MR analyses examine the putative causative role of multiple INS-R
related traits; however, each of these traits is highly polygenic and in-
strumental variables tend to explain a small amount of the variance in
cognitive ability and depression. The cognitive measures considered in
the GS:SFHS and in the UK Biobank covered the domains of cognitive
function that have been consistently implicated in INS-R and T2D in
observational studies (Benedict et al., 2012; Ekblad et al., 2015; Palta
et al., 2014). However, as the hippocampus is enriched in insulin re-
ceptors (Dore et al., 1997; Wozniak et al., 1993) and is sensitive to INS-
R and depression (Singh et al., 2018) our cognitive battery could have
beneﬁted from additional tests targeting hippocampus-linked episodic
memory (van Petten, 2004). A further limitation is that case ascer-
tainment was primarily based on self-report which may have led to
inaccuracies in the phenotype due to recall bias.
In summary, this study did not ﬁnd robust evidence for causal as-
sociations between INS-R with depression and cognitive ability. Future
work should focus on improving instrumental variables, examining a
wider range of depression and cognitive phenotypes and focusing on
biological mechanisms that may mediate the central eﬀects of INS-R.
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